In order to overcome these limitations, HLA‐I‐restricted tumour TCRs, usually of native affinity, have been expressed on CD4+ T cells such that they can be redirected to recognize HLA‐I‐restricted tumour antigens and contribute to the anti‐tumour immunity 17, 18, 19, 20, 21. The gene discussed is CD4; the disease is neoplasm.